A newly published systematic review and meta-analysis in the journal Diabetes Research and Clinical Practice suggests that GLP-1 receptor agonists — the drug class that includes Ozempic and Wegovy — may help reduce serious leg complications in people with peripheral artery disease (PAD), a condition where narrowed arteries restrict blood flow to the limbs.
What the Research Found
The study examined whether GLP-1-based therapies, including GLP-1 receptor agonists (GLP-1RAs) and the dual incretin agonist tirzepatide (the active ingredient in Mounjaro and Zepbound), could lower the risk of major adverse limb events (MALE) in people with PAD. MALE is a clinical term for serious leg complications that can include severe limb ischemia, amputation, or the need for emergency vascular procedures.
The review also looked at major adverse cardiovascular events (MACE) and mortality outcomes. Researchers noted that while GLP-1-based therapies have already demonstrated well-established cardiometabolic benefits in large cardiovascular outcome trials, their specific effects on limb outcomes in PAD patients had remained unclear — until now.
Why This Matters for PAD Patients
Peripheral artery disease affects millions of people, and many PAD patients also have type 2 diabetes or obesity — the same populations most likely to be prescribed GLP-1 medications. The overlap is significant: uncontrolled blood sugar and excess weight both accelerate arterial damage, putting patients at heightened risk for limb-threatening complications.
If GLP-1 drugs can meaningfully reduce the risk of major limb events on top of their known heart and metabolic benefits, that could influence prescribing decisions for patients managing both PAD and conditions like type 2 diabetes or obesity.
Key takeaway: A new meta-analysis of real-world studies suggests GLP-1 drugs like semaglutide and tirzepatide may reduce the risk of serious limb complications in peripheral artery disease — a potential benefit beyond their established heart and metabolic effects.
Important Limitations to Keep in Mind
The meta-analysis drew on real-world studies rather than randomized controlled trials, which means factors outside the researchers' control could have influenced the results. Real-world data can reflect differences in who gets prescribed these medications, how consistently patients take them, and what other treatments they receive simultaneously. These limitations don't invalidate the findings, but they do mean the results should be interpreted with appropriate caution pending further dedicated research.
What to Watch Next
This meta-analysis is likely to prompt calls for dedicated clinical trials specifically designed to test GLP-1 drugs in PAD populations. Researchers and clinicians will be watching for whether tirzepatide, which targets both GLP-1 and GIP receptors, shows any differential benefit compared to GLP-1 receptor agonists alone. Patients with PAD who are already taking these medications for diabetes or weight management should discuss these emerging findings with their vascular specialist or prescriber.
Frequently Asked Questions
As with any emerging research, these findings should not change your current medication routine without guidance from your healthcare provider. If you have peripheral artery disease or concerns about limb health, speak with your prescriber or a vascular specialist to discuss what this evidence may mean for your specific treatment plan.
- Peer-reviewed journal article, 'GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies,' Diabetes Research and Clinical Practice, date not specified in source material.